Peter Gruss, president of the Max Planck Society, has been nominated to join the board of directors of Actelion Pharmaceuticals Ltd, a Swiss-based biopharmaceutical company. Professor Dr Gruss is a molecular biologist and recipient of the Gottfried Wilhelm Leibniz Prize, Germany’s highest honour for research. He is expected to be voted onto the board in May 2012. His nomination was announced on 30 November, 2011.
Copyright 2011 Evernow Publishing Ltd